Showing 1 to 1 of 1 results
elmundo.es
🌐 85% Global Worthiness


Oral Medication Shows Significant Weight Loss in Obesity Treatment
A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.
Oral Medication Shows Significant Weight Loss in Obesity Treatment
A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results